Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410488 · ClinicalTrials.gov registry record · NA
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT00410488: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00410488 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00410488, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare 2 treatment schedules of Aloxi (palonosetron) in patients with sarcoma who are receiving chemotherapy with adriamycin and ifosfamide. The safety of the drug and schedules will be studied. The effect of palonosetron on patients' quality of life (QOL) will also be studied.
Interventions
- DRUG Adriamycin
- DRUG Palonosetron - Single Dose
- DRUG Palonosetron - Triple Dose
- DRUG Ifosfamide chemotherapy (AI)
- DRUG Zinecard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00410488
The ClinicalTrials.gov registry entry for NCT00410488 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Adriamycin is the first listed.
NCT00410488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00410488 about?
NCT00410488 is a clinical study titled "Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)". The goal of this clinical research study is to compare 2 treatment schedules of Aloxi (palonosetron) in patients with sarcoma who are receiving chemotherapy with adriamycin and ifosfamide. The safety of the drug and schedules will be studied. The effect of palonosetron on patients' quality of life (...
What is the current status of trial NCT00410488?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2006-12. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00410488?
The interventions under investigation include: Adriamycin (DRUG), Palonosetron - Single Dose (DRUG), Palonosetron - Triple Dose (DRUG), Ifosfamide chemotherapy (AI) (DRUG), Zinecard (DRUG).
Who is sponsoring clinical trial NCT00410488?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.